# Purely Proteins

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purely-proteins

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.purelyproteins.com
- Total disclosed funding: $3.6M
- Latest round: Series B (Dec 1, 2004)
- Investors on record: 3

## About

Purely Proteins specializes in the sale and leasing of premium domain names, particularly focusing on the domain PurelyProteins.com, facilitating businesses in the health and nutrition sectors to enhance their online presence.Founded in 2002 and headquartered in Cambridge, UK, Purely Proteins is focused on domain name transactions. The company received a total funding of USD 3.60 mn, led by Avlar BioVentures in its SERIES B round. Notably, YFM Equity Partners exited its stake in December 2005. The firm has completed three deals since its inception, positioning itself as a niche player in the digital real estate market.PurelyProteins.com primarily engages in the sale and leasing of domain names, specifically the premium domain PurelyProteins.com. Their offerings allow clients to buy or lease domain names, targeting businesses in the health and nutrition sectors. The service simplifies the acquisition of valuable domain assets, ensuring secure transactions and providing support throughout the process. This company caters globally, attracting a diverse clientele aiming to enhance their digital identities.For the year 2009, Purely Proteins reported a revenue of USD 232.6 mn. The revenue model consists of direct sales and leasing of domain names, with options for immediate ownership at USD 2,499 or a leasing option at USD 625 per month. This pricing strategy serves a broad range of clients, including entrepreneurs and larger enterprises seeking premium digital properties.Purely Proteins is planning to expand its services to new markets, specifically targeting emerging economies in Asia and Latin America by the end of 2024. The recent funding of USD 3.60 mn will support these initiatives, focusing on enhancing marketing efforts and developing new products aimed at improving user experience in domain transactions. The company aims to introduce additional premium domain offerings in 2025, furthering its reach in the global market.

## Funding rounds

- Series B, Dec 1, 2004, $3.6M — Avlar BioVentures, YFM Equity Partners, BioScience Ventures Group

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Series B
- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Series B
- BioScience Ventures Group (https://capitalatlas.ai/funds/bioscience-ventures-group) — Series B